The content on this site is intended for healthcare professionals only
Dr Jamal Zekri speaks to ecancer about his study investigating biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer.
Dr Zekri talks about the background and design of his study. He says that the study reported the tolerability and efficacy of biweekly cetuximab in combination with biweekly XELOX or XELIRI in patients with RAS wild-type metastatic colorectal cancer (RAS-WT mCRC).
The results of the study showed that biweekly cetuximab in combination with XELOX or XELIRI is effective and well tolerated.
Read the full study here.
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer
Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Understanding the use of PARPi combinations to treat patients with mCRPC
Durable responses in aRCC, how do we optimise treatment?
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Immunotherapy significantly increases the number of patients free from bowel cancer
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
